Skip to main content
SpringerLink
Log in

Biomarkers of Inflammation as Surrogate Markers in Detection of Vulnerable Plaques and Vulnerable Patients

  • Chapter
Cardiovascular Medicine

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Smith SC Jr, Anderson JL, Cannon RO 3rd, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation 2004;110(25):e550–553.

    Article  PubMed  Google Scholar 

  2. Pearson TA, Mensah GA, Hong Y, Smith SC Jr. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. Circulation 2004;110(25):e543–544.

    Article  PubMed  Google Scholar 

  3. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(21 suppl 1):II2–10.

    PubMed  Google Scholar 

  4. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44(10):1945–1956.

    Article  PubMed  Google Scholar 

  5. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25(5):923–931.

    Article  PubMed  CAS  Google Scholar 

  6. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286(17):2136–2142.

    Article  PubMed  CAS  Google Scholar 

  7. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancyassociated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345(14):1022–1029.

    Article  PubMed  CAS  Google Scholar 

  8. Johnson BD, Kip KE, MarrO’Quin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004;109(6):726–732.

    Article  PubMed  CAS  Google Scholar 

  9. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101(18):2149–2153.

    PubMed  CAS  Google Scholar 

  10. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22(10):1668–1673.

    Article  PubMed  CAS  Google Scholar 

  11. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101(15):1767–1772.

    PubMed  CAS  Google Scholar 

  12. Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol 2002;39(7):1133–1138.

    Article  PubMed  CAS  Google Scholar 

  13. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103(4):491–495.

    PubMed  CAS  Google Scholar 

  14. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104(19):2266–2268.

    Article  PubMed  CAS  Google Scholar 

  15. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003;107(3):370–371.

    Article  PubMed  Google Scholar 

  16. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106(12):1439–1441.

    Article  PubMed  CAS  Google Scholar 

  17. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005;288(4):E741–747.

    Article  PubMed  CAS  Google Scholar 

  18. Mosca L. C-reactive protein—to screen or not to screen? N Engl J Med 2002;347(20):1615–1617.

    Article  PubMed  Google Scholar 

  19. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347(20):1557–1565.

    Article  PubMed  CAS  Google Scholar 

  20. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99(2):237–242.

    PubMed  CAS  Google Scholar 

  21. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. Creactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002;144(2):233.

    Article  PubMed  CAS  Google Scholar 

  22. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98(8):731–733.

    PubMed  CAS  Google Scholar 

  23. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002;55(5):445.

    Article  PubMed  Google Scholar 

  24. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of Creactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99(7):855–860.

    PubMed  CAS  Google Scholar 

  25. Benamer H, Steg PG, Benessiano J, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol 1998;82(7):845.

    Article  PubMed  CAS  Google Scholar 

  26. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34(5):1512.

    Article  PubMed  CAS  Google Scholar 

  27. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001;32(4):917–924.

    PubMed  Google Scholar 

  28. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002;105(7):800–803.

    Article  PubMed  Google Scholar 

  29. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279(18):1477–1482.

    Article  PubMed  CAS  Google Scholar 

  30. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321(7255):199–204.

    Article  PubMed  CAS  Google Scholar 

  31. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350(14):1387–1397.

    Article  PubMed  CAS  Google Scholar 

  32. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47(3):426–430.

    PubMed  CAS  Google Scholar 

  33. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100(3):230–235.

    PubMed  CAS  Google Scholar 

  34. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106(12):1447–1452.

    Article  PubMed  CAS  Google Scholar 

  35. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286(1):64–70.

    Article  PubMed  CAS  Google Scholar 

  36. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108(19):2292–2297.

    Article  PubMed  Google Scholar 

  37. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352(1):29–38.

    Article  PubMed  CAS  Google Scholar 

  38. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20–28.

    Article  PubMed  CAS  Google Scholar 

  39. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282(22):2131–2135.

    Article  PubMed  CAS  Google Scholar 

  40. Festa A, D’Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102(1):42–47.

    PubMed  CAS  Google Scholar 

  41. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43(1):52–58.

    PubMed  CAS  Google Scholar 

  42. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005;165(2):221–226.

    Article  PubMed  Google Scholar 

  43. Keefer CS, Resnik WH. Angina pectoris: a syndrome caused by anoxemia of the myocardium. Arch Intern Med 1928;41(6):769–807.

    Google Scholar 

  44. Zalokar JB, Richard JL, Claude JR. Leukocyte count, smoking, and myocardial infarction. N Engl J Med 1981;304(8):465–468.

    Article  PubMed  CAS  Google Scholar 

  45. Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985;254(14):1932–1937.

    Article  PubMed  Google Scholar 

  46. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol 1992;136(1):59–70.

    PubMed  CAS  Google Scholar 

  47. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA 1992;267(9):1253–1256.

    Article  PubMed  CAS  Google Scholar 

  48. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96(4):1102–1108.

    PubMed  CAS  Google Scholar 

  49. Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and white men and women: atherosclerosis risk in communities study. Am J Epidemiol 2001;154(8):758–764.

    Article  PubMed  CAS  Google Scholar 

  50. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54(3):316–322.

    Article  PubMed  CAS  Google Scholar 

  51. Amaro A, Gonzalez-Juanatey JR, Iglesias C, et al. Leukocyte count as a predictor of the severity ischaemic heart disease as evaluated by coronary angiography. Rev Port Cardiol 1993;12(11):899, 913–917.

    Google Scholar 

  52. Kostis JB, Turkevich D, Sharp J. Association between leukocyte count and the presence and extent of coronary atherosclerosis as determined by coronary arteriography. Am J Cardiol 1984;53(8):997–999.

    Article  PubMed  CAS  Google Scholar 

  53. Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD. White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985;54(3):700–703.

    PubMed  CAS  Google Scholar 

  54. Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project. Circulation 1982;66(2):401–414.

    PubMed  CAS  Google Scholar 

  55. Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction. Am J Cardiol 2001;88(11):1221–1224.

    Article  PubMed  CAS  Google Scholar 

  56. Furman MI, Becker RC, Yarzebski J, Savegeau J, Gore JM, Goldberg RJ. Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction. Am J Cardiol 1996;78(8):945–948.

    Article  PubMed  CAS  Google Scholar 

  57. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001;87(5):636–639, A10.

    Article  PubMed  CAS  Google Scholar 

  58. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000;102(19):2329–2334.

    PubMed  CAS  Google Scholar 

  59. Mueller C, Neumann FJ, Perruchoud AP, Buettner HJ. White blood cell count and long-term mortality after non-ST elevation acute coronary syndrome treated with very early revascularisation. Heart 2003;89(4):389–392.

    Article  PubMed  CAS  Google Scholar 

  60. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy—Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 2002;40(10):1761–1768.

    Article  PubMed  Google Scholar 

  61. Prentice RL, Szatrowski TP, Fujikura T, Kato H, Mason MW, Hamilton HH. Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol 1982;116(3):496–509.

    PubMed  CAS  Google Scholar 

  62. Olivares R, Ducimetiere P, Claude JR. Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol 1993;137(1):49–53.

    PubMed  CAS  Google Scholar 

  63. Sweetnam PM, Thomas HF, Yarnell JW, Baker IA, Elwood PC. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am J Epidemiol 1997;145(5):416–421.

    PubMed  CAS  Google Scholar 

  64. Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165(5):500–508.

    Article  PubMed  Google Scholar 

  65. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1994;1213(1):34–38.

    PubMed  CAS  Google Scholar 

  66. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoproteinassociated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343(16):1148–1155.

    Article  PubMed  CAS  Google Scholar 

  67. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38(5):1302–1306.

    Article  PubMed  CAS  Google Scholar 

  68. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middleaged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109(7):837–842.

    Article  PubMed  CAS  Google Scholar 

  69. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110(14):1903–1908.

    Article  PubMed  CAS  Google Scholar 

  70. Oei HH, van der Meer IM, Hofman A, et al. Lipoproteinassociated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111(5):570–575.

    Article  PubMed  CAS  Google Scholar 

  71. Macphee CH, Nelson JJ. An evolving story of lipoproteinassociated phospholipase A2 in atherosclerosis and cardiovascular risk prediction. Eur Heart J 2005;26(2):107–109.

    Article  PubMed  CAS  Google Scholar 

  72. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26(2):137–144.

    Article  PubMed  CAS  Google Scholar 

  73. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110(11):1406–1412.

    Article  PubMed  CAS  Google Scholar 

  74. Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003;44(5):927–934.

    Article  PubMed  CAS  Google Scholar 

  75. Blackie JA, Bloomer JC, Brown MJ, et al. The discovery of SB-435495. A potent, orally active inhibitor of lipoproteinassociated phospholipase A(2) for evaluation in man. Bioorg Med Chem Lett 2002;12(18):2603–2606.

    Article  PubMed  CAS  Google Scholar 

  76. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448–454.

    Article  PubMed  CAS  Google Scholar 

  77. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108(12):1440–1445.

    Article  PubMed  CAS  Google Scholar 

  78. Brennan M-L, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349(17):1595–1604.

    Article  PubMed  CAS  Google Scholar 

  79. Cosin-Sales J, Christiansen M, Kaminski P, et al. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004;109(14):1724–1728.

    Article  PubMed  CAS  Google Scholar 

  80. Beaudeux J-L, Burc L, Imbert-Bismut F, et al. Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2003;23(1):7e–10.

    Article  CAS  Google Scholar 

  81. Lund J, Qin Q-P, Ilva T, et al. Circulating pregnancy associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003;108(16):1924–1926.

    Article  PubMed  Google Scholar 

  82. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005;45(2):229–237.

    Article  PubMed  CAS  Google Scholar 

  83. Yamada T, Miida T. Serum amyloid A remains at physiological concentrations in coronary atherosclerosis. Clin Chem 1997;43(1):193.

    PubMed  CAS  Google Scholar 

  84. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999;45(11):1967–1973.

    PubMed  CAS  Google Scholar 

  85. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331(7):417–424.

    Article  PubMed  CAS  Google Scholar 

  86. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 2000;35(2):358–362.

    Article  PubMed  CAS  Google Scholar 

  87. Harb TS, Zareba W, Moss AJ, et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002;89(2):216–221.

    Article  PubMed  CAS  Google Scholar 

  88. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98(9):839–844.

    PubMed  CAS  Google Scholar 

  89. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331(7):417–424.

    Article  PubMed  CAS  Google Scholar 

  90. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108(13):1560–1566.

    Article  PubMed  CAS  Google Scholar 

  91. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89(12):1092–1103.

    Article  PubMed  CAS  Google Scholar 

  92. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100(6):614–620.

    PubMed  CAS  Google Scholar 

  93. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348(12):1104–1111.

    Article  PubMed  CAS  Google Scholar 

  94. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108(9):1049–1052.

    Article  PubMed  CAS  Google Scholar 

  95. Kinlay S, Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110(4):386–391.

    Article  PubMed  CAS  Google Scholar 

  96. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble Pselectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004;109(21):2524–2528.

    Article  PubMed  CAS  Google Scholar 

  97. Cipollone F, Ferri C, Desideri G, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003;108(22):2776–2782.

    Article  PubMed  CAS  Google Scholar 

  98. L’Allier PL, Tardif JC, Gregoire J, et al. Sustained elevation of serum CD40 ligand levels one month after coronary angioplasty predicts angiographic restenosis. Can J Cardiol 2005;21(6):495–500.

    PubMed  Google Scholar 

  99. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990;7(2):147–159.

    PubMed  CAS  Google Scholar 

  100. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results From the Health ABC Study. Circulation 2003;108(19):2317–2322.

    Article  PubMed  CAS  Google Scholar 

  101. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 2002;288(8):980–987.

    Article  PubMed  CAS  Google Scholar 

  102. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107(11):1486–1491.

    Article  PubMed  CAS  Google Scholar 

  103. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351(25):2599–2610.

    Article  PubMed  CAS  Google Scholar 

  104. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106(1):24–30.

    Article  PubMed  CAS  Google Scholar 

  105. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104(14):1598–1603

    Article  PubMed  CAS  Google Scholar 

  106. Blankenberg S, Luc G, Ducimetiere P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108(20):2453–2459.

    Article  PubMed  CAS  Google Scholar 

  107. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003;107(16):2109–2114.

    Article  PubMed  CAS  Google Scholar 

  108. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003;169(2):203–214.

    Article  PubMed  CAS  Google Scholar 

  109. Ballantyne CM, Entman ML. Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation 2002;106(7):766–767.

    Article  PubMed  CAS  Google Scholar 

  110. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96(12):4219–4225.

    PubMed  CAS  Google Scholar 

  111. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351(9096):88–92.

    Article  PubMed  CAS  Google Scholar 

  112. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836–843.

    Article  PubMed  CAS  Google Scholar 

  113. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358(9286):971–976.

    Article  PubMed  CAS  Google Scholar 

  114. Luc G, Arveiler D, Evans A, et al. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 2003;170(1):169–176.

    Article  PubMed  CAS  Google Scholar 

  115. de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000;36(2):423–426.

    Article  PubMed  Google Scholar 

  116. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104(12):1336–1342.

    Article  PubMed  CAS  Google Scholar 

  117. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002;106(7):820–825.

    Article  PubMed  CAS  Google Scholar 

  118. Labarrere CA, Nelson DR, Miller SJ, et al. Value of serumsoluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. Circulation 2000;102(13):1549–1555.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Mohammad Madjid MD

  2. Texas Heart Institute, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Samuel Ward Casscells MD & James T. Willerson MD

Authors
  1. Mohammad Madjid MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Ward Casscells MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James T. Willerson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Texas Health Science Center in Houston, Houston

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  2. Texas Heart Institute, Houston, TX, USA

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  3. Department of Cardiology, University of Maastricht, Masstricht, The Netherlands

    Hein J. J. Wellens MD (Emeritus Professor) (Emeritus Professor)

  4. Rasmussen Center for Cardiovascular Disease Prevention Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA

    Jay N. Cohn MD (Professor of Medicine and Director) (Professor of Medicine and Director)

  5. Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    David R. Holmes Jr. MD (Consultant, Professor of Medicine and Scripps Professor) (Consultant, Professor of Medicine and Scripps Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Madjid, M., Casscells, S.W., Willerson, J.T. (2007). Biomarkers of Inflammation as Surrogate Markers in Detection of Vulnerable Plaques and Vulnerable Patients. In: Willerson, J.T., Wellens, H.J.J., Cohn, J.N., Holmes, D.R. (eds) Cardiovascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84628-715-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-715-2_28

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-188-4

  • Online ISBN: 978-1-84628-715-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation